(Q38092463)

28 August 2017

Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery (English)

1 reference

28 August 2017

Kazuhiko Matsuo

1

1 reference

28 August 2017

Sachiko Hirobe

series ordinal

2

1 reference

28 August 2017

Naoki Okada

series ordinal

3

1 reference

28 August 2017

Shinsaku Nakagawa

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 March 2013

1 reference

28 August 2017

13

1 reference

inferred from page(s)

published in

Vaccine

1 reference

28 August 2017

31

1 reference

28 August 2017

19

1 reference

28 August 2017

2403-2415

1 reference

Risk perceptions related to SARS and avian influenza: theoretical foundations of current empirical research.

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Probable person-to-person transmission of avian influenza A (H5N1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Tuberculosis, a re-emergent disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Professional antigen-presenting cells of the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1- and Th2-polarizing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Breaching the skin's barrier to drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Innate immune modulation of keratinocytes by antikeratin 16 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Expression of functional toll-like receptors on cultured human epidermal keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Functional expression of the intracellular pattern recognition receptor NOD1 in human keratinocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Expression of toll-like receptor 2, NOD2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Dermal fibroblasts promote the migration of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Langerhans Cells Do Not Produce Interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Changing views of the role of Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Identification of a novel population of Langerin+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

The origin and development of nonlymphoid tissue CD103+ DCs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transdermal delivery of metoprolol by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Application of electroporation in DNA vaccination protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transdermal iontophoresis of insulin. V. Effect of terpenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transdermal iontophoretic delivery of salmon calcitonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transdermal delivery of timolol and atenolol using electroporation and iontophoresis in combination: a mechanistic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous immunisation assisted by low-frequency ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

An investigation into the combination of low frequency ultrasound and liposomes on skin permeability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Low-frequency ultrasound as a transcutaneous immunization adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Preventing contamination between injections with multiple-use nozzle needle-free injectors: a safety trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous immunization: a human vaccine delivery strategy using a patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Characterization of transcutaneous protein delivery by a hydrogel patch in animal, human, and tissue-engineered skin models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Compositional optimization and safety assessment of a hydrogel patch as a transcutaneous immunization device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Relation of electrical properties of skin to structure and physiologic state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Water increases the fluidity of intercellular membranes of stratum corneum: correlation with water permeability, elastic, and electrical resistance properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Penetration of metallic nanoparticles in human full-thickness skin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Coated microneedle arrays for transcutaneous delivery of live virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Bacillus Calmette-Guérin vaccination using a microneedle patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Dissolving polymer microneedle patches for influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Improved influenza vaccination in the skin using vaccine coated microneedles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Multidrug release based on microneedle arrays filled with pH-responsive PLGA hollow microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Nanoparticles for transcutaneous vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Chitosan-based nanoparticles for improving immunization against hepatitis B infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

The use of biodegradable polymeric nanoparticles in combination with a low-pressure gene gun for transdermal DNA delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Elastic liposomes mediated transcutaneous immunization against Hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Preparation and characterization of diphtheria toxoid-loaded elastic vesicles for transcutaneous immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Development of novel fusogenic vesosomes for transcutaneous immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Microneedles in clinical practice--an exploratory study into the opinions of healthcare professionals and the public

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Serum antibody responses after intradermal vaccination against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Dose sparing with intradermal injection of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.022

Microneedle delivery: clinical studies and emerging medical applications

7 January 2021

1 reference

12 December 2020

Malaria: an emerging and re-emerging global plague

1 reference

12 December 2020

The cost of unsafe injections

1 reference

12 December 2020

Mass inoculation of the Salk polio vaccine with the multiple dose jet injector

1 reference

12 December 2020

Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo

1 reference

12 December 2020

Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin

1 reference

12 December 2020

Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes

1 reference

12 December 2020

10.1016/J.VACCINE.2013.03.022

Identifiers

DOI

1 reference

28 August 2017

1 reference